Carine Masquefa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4352467/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	In vitro and in vivo anti-tumoral activities of imidazo[1,2-a]quinoxaline, imidazo[1,5-a]quinoxaline, and pyrazolo[1,5-a]quinoxaline derivatives. Bioorganic and Medicinal Chemistry, 2008, 16, 6601-6610.	1.4	104
2	Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes. European Journal of Medicinal Chemistry, 2020, 193, 112238.	2.6	77
3	New imidazo[1,2-a]quinoxaline derivatives: Synthesis and in vitro activity against human melanoma. European Journal of Medicinal Chemistry, 2009, 44, 3406-3411.	2.6	45
4	EAPB0203, a member of the imidazoquinoxaline family, inhibits growth and induces caspase-dependent apoptosis in T-cell lymphomas and HTLV-l–associated adult T-cell leukemia/lymphoma. Blood, 2008, 111, 3770-3777.	0.6	36
5	New imidazoquinoxaline derivatives: Synthesis, biological evaluation on melanoma, effect on tubulin polymerization and structure–activity relationships. Bioorganic and Medicinal Chemistry, 2016, 24, 2433-2440.	1.4	32
6	Design and synthesis of novel imidazo[1,2- a]quinoxalines as PDE4 inhibitors. Bioorganic and Medicinal Chemistry, 2004, 12, 1129-1139.	1.4	30
7	Imidazo[1,2-a]quinoxalines: synthesis and cyclic nucleotide phosphodiesterase inhibitory activity. European Journal of Medicinal Chemistry, 2001, 36, 255-264.	2.6	26
8	Pharmacology of EAPB0203, a novel imidazo[1,2-a]quinoxaline derivative with anti-tumoral activity on melanoma. European Journal of Pharmaceutical Sciences, 2010, 39, 23-29.	1.9	24
9	Imidazoquinoxaline derivative EAPB0503: A promising drug targeting mutant nucleophosmin 1 in acute myeloid leukemia. Cancer, 2017, 123, 1662-1673.	2.0	24
10	EAPB0503: An Imiquimod analog with potent in vitro activity against cutaneous leishmaniasis caused by Leishmania major and Leishmania tropica. PLoS Neglected Tropical Diseases, 2018, 12, e0006854.	1.3	24
11	Imidazo[1,2-a]pyrazine, Imidazo[1,5-a]quinoxaline andÂPyrazolo[1,5-a]quinoxaline derivatives as IKK1 and IKK2 inhibitors. European Journal of Medicinal Chemistry, 2017, 138, 909-919.	2.6	22
12	Imidazoquinoxaline anticancer derivatives and imiquimod interact with tubulin: Characterization of molecular microtubule inhibiting mechanisms in correlation with cytotoxicity. PLoS ONE, 2017, 12, e0182022.	1.1	20
13	New IKK inhibitors: Synthesis of new imidazo[1,2-a]quinoxaline derivatives using microwave assistance and biological evaluation as IKK inhibitors. European Journal of Medicinal Chemistry, 2016, 115, 268-274.	2.6	16
14	EAPB0503, a novel imidazoquinoxaline derivative, inhibits growth and induces apoptosis in chronic myeloid leukemia cells. Anti-Cancer Drugs, 2014, 25, 624-632.	0.7	15
15	Metabolism and Pharmacokinetics of EAPB0203 and EAPB0503, Two Imidazoquinoxaline Compounds Previously Shown to Have Antitumoral Activity on Melanoma and T-Lymphomas. Drug Metabolism and Disposition, 2010, 38, 1836-1847.	1.7	14
16	Characterization of a New Anticancer Agent, EAPB0203, and Its Main Metabolites: Nuclear Magnetic Resonance and Liquid Chromatography–Mass Spectrometry Studies. Analytical Chemistry, 2012, 84, 9865-9872.	3.2	12
17	Imidazo[1,2-a]quinoxalines Derivatives Grafted with Amino Acids: Synthesis and Evaluation on A375 Melanoma Cells. Molecules, 2018, 23, 2987.	1.7	12
18	Imiquimod Targets Toxoplasmosis Through Modulating Host Toll-Like Receptor-MyD88 Signaling. Frontiers in Immunology, 2021, 12, 629917.	2.2	12

CARINE MASQUEFA

#	Article	IF	CITATIONS
19	Quantitation of imidazo[1,2â€ <i>a</i>]quinoxaline derivatives in human and rat plasma using LC/ESIâ€MS. Journal of Separation Science, 2009, 32, 1363-1373.	1.3	11
20	lmidazo[1,2-a]quinoxalines for melanoma treatment with original mechanism of action. European Journal of Medicinal Chemistry, 2021, 212, 113031.	2.6	11
21	Structural characterization of in vitro metabolites of the new anticancer agent EAPB0503 by liquid chromatography–tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2014, 88, 429-440.	1.4	10
22	1-[1-(2-Benzo[b]thiopheneyl)cyclohexyl]piperidine Hydrochloride (BTCP) Yields Two Active Primary Metabolites in Vitro:A Synthesis, Identification from Rat Liver Microsome Extracts, and Affinity for the Neuronal Dopamine Transporter. Journal of Medicinal Chemistry, 1997, 40, 4019-4025.	2.9	9
23	1-[1-(2-Benzo[b]thiopheneyl)cyclohexyl]piperidine hydrochloride (BTCP) yields two active primary metabolites in vivo. European Journal of Pharmaceutical Sciences, 2000, 9, 345-354.	1.9	8
24	EAPB0503, an Imidazoquinoxaline Derivative Modulates SENP3/ARF Mediated SUMOylation, and Induces NPM1c Degradation in NPM1 Mutant AML. International Journal of Molecular Sciences, 2022, 23, 3421.	1.8	7
25	Fluorescence Study of Imidazoquinoxalines. Journal of Fluorescence, 2017, 27, 1607-1611.	1.3	5
26	Lipid nanocapsules formulation and cellular activities evaluation of a promising anticancer agent: EAPB0503. International Journal of Pharmaceutical Investigation, 2017, 7, 155.	0.2	5
27	Methylation of imidazopyrazine, imidazoquinoxaline, and pyrazoloquinoxaline through Suzuki–Miyaura cross coupling. Chemistry of Heterocyclic Compounds, 2018, 54, 183-187.	0.6	3
28	Liquid chromatography-electrospray ionization-tandem mass spectrometry method for quantitative estimation of new imiqualine leads with potent anticancer activities in rat and mouse plasma. Application to a pharmacokinetic study in mice. Journal of Pharmaceutical and Biomedical Analysis, 2018, 148, 369-379.	1.4	2
29	Substantial Cellular Penetration of Fluorescent Imidazoquinoxalines. Journal of Fluorescence, 2020, 30, 1499-1512.	1.3	1
30	Fused Azolo-Quinoxalines: Candidates for Medicinal Chemistry. A Review of their Biological Applications. Current Medicinal Chemistry, 2021, 28, 712-749.	1.2	1
31	Synthesis of Some Imidazo[1,2-a]pyrazine Derivatives and Evaluation of Their Antinociceptive Activity. Clinical and Experimental Health Sciences, 2016, 6, 9-13.	0.1	0